Why the study?
Does dabigatran promote bleeding in acutely injured patients?
Does dabigatran promote bleeding in acutely injured patients?
Dabigatran use in acutely injured patients presents significant safety concerns due to bleeding risks and lack of easy reversibility.
The new oral direct thrombin inhibitor, dabigatran, is proving to be problematic in acutely injured patients, since it may promote bleeding and its effect cannot be easily reversed.
No takes yet. Share an insight, caveat, or question.
Cotton et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: